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Gluten is the main structural protein of wheat and 
other cereals (barley, rye, etc.) and is one of the princi-
pal dietary components for most of the world popula-
tion since the birth of agriculture, playing a key role in 
the development of human beings. On the other hand, 
this evolutionary trick has led to several diseases related 
to gluten exposure, the best studied of which is celiac 
disease (CD) and wheat allergy (WA). However, some in-
dividuals complain of gastrointestinal or extra-intestinal 
symptoms linked to the ingestion of gluten and disap-
pearing with gluten withdrawal, even without any his-
tological or serologic evidence of celiac disease (CD) or 
wheat allergy (FA). In most cases these patients consult 
a large number of physicians seeking the diagnosis of CD, 
but very often they are considered to be suffering from 
irritable bowel syndrome (IBS) only.
According to a recently developed consensus, the 
term “non-celiac gluten sensitivity” (NCGS) has been 
suggested for this condition, relating to “one or more of 
a variety of immunological, morphological or symptom-
atic manifestations that are induced by the ingestion of 
gluten in people in whom CD has been excluded” [1] and 
the diagnosis is possible only after exclusion of the celiac 
disease, food allergies or food-related disorders and the 
symptomatic response to a change in the diet [2]. The 
diagnostic “gold standard” for gluten sensitivity ought to 
be the double-blind placebo-controlled (DBPC) challenge, 
but it is a quite dangerous and time-consuming method 
and is therefore rarely used [3]. 
There are no objective findings or markers to sup-
port a diagnosis of gluten sensitivity and its pathogen-
esis remains obscure, although the hypothesis is based 
on a stimulation of the innate immune system by the 
gliadin. Another theory suggests that the gliadin induces 
a direct cytotoxic effect on enterocytes [4, 5]. However, 
a role for gluten proteins as the sole trigger of the associ-
ated symptoms remains to be established.
Although the patients with gluten sensitivity have 
a beneficial effect on their symptoms with the gluten-
free diet, the same new diet reduces enormously their 
quality of life. For these reasons it is important not only 
to provide the understanding of the NCGS pathogene-
sis, but also how to manage this disease to enhance the 
quality of life of the patients.
Therefore, we present a case report about a girl with 
NCGS who underwent successful wheat desensitization 
treatment.
We report the case of a 27-year-old girl with abdomi-
nal pain, diarrhea, oral itching and throat tightness after 
the ingestion of wheat products. The girl had wheat al-
lergological tests done after a previous gastroenterologi-
cal evaluation to fulfill the criteria recently proposed on 
“gluten sensitivity” [2, 6]. 
She had anti-gliadin (AGA) IgA and IgG antibodies, 
anti-transglutaminase (anti-tTG) and anti-endomysial 
(EmA) IgA antibodies, esophagogastroduodenoscopy 
with biopsy, HLA molecular typing for celiac disease and 
lactulose breath test in the gastroenterological screening 
and wheat skin prick test, specific IgE assay and basophil 
activation test for the allergological evaluation. 
At the end of the diagnostic tests, the patient met all 
the following inclusion criteria:
–  IBS-like symptoms defined according to the Rome II 
criteria [7];
–  Negative serum anti-tTG and EmA IgA antibodies;
–  Negative duodenal histology (absence of intestinal vil-
lous atrophy);
–  Negative wheat skin prick test and specific IgE assay [8];
–  Resolution of the symptoms on gluten-free diet and 
reappearance on DBPC wheat challenge [9].
Since the girl presented positive HLA DQ2 haplotype 
and lactulose breath test, she had antibiotic and probiot-
ic therapy for small intestinal bacterial overgrowth with 
a subsequent negative breath test. All allergological tests 
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were negative and, as she continued to present symp-
toms, the patient began to avoid all products containing 
wheat on her own with complete disappearance of clini-
cal manifestations. 
Therefore, we did a DBPC challenge (Table 1) with 
wheat and she presented a systemic reaction (abdominal 
pains, nausea and oral itching with mucosal hyperemia) 
after the ingestion of 15 ml of this food. 
At this point the girl underwent a wheat desensitiza-
tion treatment (Table 2) and after 21 months she was 
able to eat about 150 gr of wheat without any adverse 
reaction, starting a free dietary regimen.
In the clinical practice, an emerging problem is how 
to manage patients who experience symptoms after 
wheat ingestion in the absence of the main symptoms 
of CD or food allergy. These subjects often start gluten-
free diet on their own with a complete benefit on mani-
festations. 
The elimination diet itself reduces quality of life, lead-
ing to social, economic, psychological problems. 
Moreover, we do not know the possible complica-
tions or how strictly or for how long the diet should be 
adhered to. So gluten sensitivity needs further investiga-
tions before gluten-free foods are promoted as a remedy 
on a large scale. 
In this case report we have tried to manage our pa-
tient with the same therapeutic method we use in aller-
gic patients and we obtained good results allowing her 
to enlarge the diet without any restrictions. 
Moreover, as in allergic diseases, in NCGS we found 
a very high frequency of self-reported wheat intolerance 
that makes the patients choose the elimination diet. The 
DBPC challenge is widely used to confirm the diagnosis 
of food hypersensitivity and therefore could be a diag-
nostic marker for NCGS, able to overcome the emotional 
component that seems to be pivotal in these patients. 
In this case report we have shown how the wheat DBPC 
test could be the “gold standard” method also to make 
the diagnosis in these subjects, excluding the subjec-
tive component that seems to prevail in this disease. 
Carroccio et al. [3] have reached the same conclusions 
and demonstrated that DBPC challenge confirmed the 
diagnosis of NCGS in a relevant percentage of patients. 
Although DBPC test seems to have a high diagnostic ac-
curacy, its use is limited to the research setting because 
it is expensive and time-consuming [10]; therefore, a rea-
sonable approach in clinical practice would be to perform 
cheaper and easier single-blind gluten challenge tests.
Although this is only a case report, our results repre-
sent a new approach in research on NCGS and could pro-
vide a future perspective of the study for its management.
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Table 1. Wheat DBPC challenge (boiled semolina 40 mg/ml)
Day 1:
Dilution 1 : 100 0.1 ml
Dilution 1 : 100 0.5 ml
Dilution 1 : 100 1 ml
Dilution 1 : 10 0.2 ml
Dilution 1 : 10 0.3 ml
Dilution 1 : 10 0.4 ml
Day 2:
Pure solution 0.2 ml
Pure solution 0.5 ml
Pure solution 1 ml
Pure solution 2 ml
Pure solution 5 ml
Pure solution 10 ml
Table 2. Wheat desensitization treatment
Wheat Days Dilution Starting dose
(once a day) 
Final dose
(3 times a day) 
Daily dose [g]
Semolina
(0.02 g/ml) 
1–18 10–6 1 ml 10 ml 0.6 × 10–6 
19–30 10–4 1 ml 10 ml 0.6 × 10–4 
31–39 10–3 3 ml 10 ml 0.6 × 10–3 
40–48 10–2 3 ml 10 ml 0.6 × 10–2
49–57 10–1 3 ml 10 ml 0.06 
58–120 Pure solution 3 ml 75 ml 4.5 
Pasta
(1 spagh/portion = 1.2 g) 
121–144 Pure solution 1 spaghetti 4.5 spaghetti 16.2 
145–215 Pure solution 6 spaghetti 41 spaghetti 147 
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